Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

• Type of Material: Article
• Authors: Jessica Howard-Anderson, Emory University; Stephanie Pouch, Emory University; Mary Elizabeth Sexton, Emory University; Aneesh K Mehta, Emory University; Andrew L Smith, Emory University; G Marshall Lyon III, Emory University; Rachel Jacqueline Friedman-Moraco, Emory University
• Language: English
• Date: 2019-09-01
• Publisher: Oxford University Press (OUP)
• Publication Version: Final Published Version
• Copyright Statement: © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofz235
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• ISSN: 2328-8957
• Volume: 6
• Issue: 9
• Start Page: ofz235
• End Page: ofz235
• Grant/Funding Information: J.H.-A. is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR002378 and TL1TR002382).
• Keywords: Staphylococcus aureus; Infectious Diseases; left ventricular assist devices; SKIN; dalbavancin; Science & Technology; Microbiology; Life Sciences & Biomedicine; Immunology
• Research Categories: Health Sciences, Immunology; Biology, Microbiology

Abstract

Left ventricular assist device infections (LVADIs) are common but challenging to treat, often requiring prolonged courses of intravenous antibiotics. Dalbavancin could have a role in treating patients with chronic LVADIs given its less frequent dosing requirements. Here, we illustrate a case in which dalbavancin was used as suppressive therapy for an LVADI for greater than 7 months.